Is Evoke Pharma Stock a Good Investment?
Evoke Pharma Investment Advice | EVOK |
- Examine Evoke Pharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Evoke Pharma's leadership team and their track record. Good management can help Evoke Pharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Evoke Pharma's business and its evolving consumer preferences.
- Compare Evoke Pharma's performance and market position to its competitors. Analyze how Evoke Pharma is positioned in terms of product offerings, innovation, and market share.
- Check if Evoke Pharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Evoke Pharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Evoke Pharma stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Evoke Pharma is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Evoke Pharma Stock
Researching Evoke Pharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 38.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.79. Some equities with similar Price to Book (P/B) outperform the market in the long run. Evoke Pharma recorded a loss per share of 2.33. The entity had not issued any dividends in recent years. The firm had 1:12 split on the 23rd of May 2022.
To determine if Evoke Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Evoke Pharma's research are outlined below:
| Evoke Pharma generated a negative expected return over the last 90 days | |
| Evoke Pharma has high historical volatility and very poor performance | |
| Evoke Pharma has some characteristics of a very speculative penny stock | |
| Evoke Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 5.18 M. Net Loss for the year was (7.79 M) with profit before overhead, payroll, taxes, and interest of 2.14 M. | |
| Evoke Pharma currently holds about 13.45 M in cash with (4.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Evoke Pharma has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: StockNews.com Initiates Coverage on Evoke Pharma - Defense World |
Evoke Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Evoke Pharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Evoke Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact Evoke Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Evoke Pharma's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-03-14 | 2023-12-31 | -0.5 | -0.59 | -0.09 | 18 | ||
2023-05-15 | 2023-03-31 | -0.58 | -0.67 | -0.09 | 15 | ||
2023-11-09 | 2023-09-30 | -0.62 | -0.51 | 0.11 | 17 | ||
2022-08-10 | 2022-06-30 | -0.6 | -0.71 | -0.11 | 18 | ||
2021-11-10 | 2021-09-30 | -0.84 | -0.72 | 0.12 | 14 | ||
2021-08-12 | 2021-06-30 | -0.96 | -0.84 | 0.12 | 12 | ||
2018-11-13 | 2018-09-30 | -0.96 | -1.08 | -0.12 | 12 | ||
2023-08-10 | 2023-06-30 | -0.73 | -0.56 | 0.17 | 23 |
Know Evoke Pharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Evoke Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Evoke Pharma backward and forwards among themselves. Evoke Pharma's institutional investor refers to the entity that pools money to purchase Evoke Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Vanguard Group Inc | 2023-12-31 | 29.9 K | Geode Capital Management, Llc | 2023-12-31 | 27.1 K | Tower Research Capital Llc | 2023-12-31 | 6.4 K | Ubs Group Ag | 2023-12-31 | 2.9 K | Blackrock Inc | 2023-12-31 | 1.5 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 375 | Goss Wealth Management Llc | 2023-12-31 | 208 | Royal Bank Of Canada | 2023-12-31 | 28.0 | Wells Fargo & Co | 2023-12-31 | 26.0 | Cwm, Llc Duplicate | 2023-12-31 | 16.0 | Concord Wealth Partners | 2023-12-31 | 0.0 |
Evoke Pharma's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.88 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Evoke Pharma's market, we take the total number of its shares issued and multiply it by Evoke Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Evoke Pharma's profitablity analysis
Evoke Pharma's profitability indicators refer to fundamental financial ratios that showcase Evoke Pharma's ability to generate income relative to its revenue or operating costs. If, let's say, Evoke Pharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Evoke Pharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Evoke Pharma's profitability requires more research than a typical breakdown of Evoke Pharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.10) | (1.16) | |
| Return On Capital Employed | (1.84) | (1.93) | |
| Return On Assets | (1.10) | (1.16) | |
| Return On Equity | 3.02 | 3.17 |
Determining Evoke Pharma's profitability involves analyzing its financial statements and using various financial metrics to determine if Evoke Pharma is a good buy. For example, gross profit margin measures Evoke Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Evoke Pharma's profitability and make more informed investment decisions.
The data published in Evoke Pharma's official financial statements usually reflect Evoke Pharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Evoke Pharma. For example, before you start analyzing numbers published by Evoke accountants, it's critical to develop an understanding of what Evoke Pharma's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Evoke Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Evoke Pharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Evoke Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Evoke Pharma. Please utilize our Beneish M Score to check the likelihood of Evoke Pharma's management manipulating its earnings.
Evaluate Evoke Pharma's management efficiency
Evoke Pharma has return on total asset (ROA) of (0.4909) % which means that it has lost $0.4909 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.3544) %, meaning that it created substantial loss on money invested by shareholders. Evoke Pharma's management efficiency ratios could be used to measure how well Evoke Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is expected to rise to 3.17 this year, although the value of Return On Tangible Assets will most likely fall to (1.16). At this time, Evoke Pharma's Liabilities And Stockholders Equity is quite stable compared to the past year. Change To Liabilities is expected to rise to about 101.4 K this year, although the value of Total Current Liabilities will most likely fall to about 2.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.77) | (0.81) | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | (0.77) | (0.81) | |
| Enterprise Value Over EBITDA | (0.51) | (0.53) | |
| Price Book Value Ratio | (1.36) | (1.29) | |
| Enterprise Value Multiple | (0.51) | (0.53) | |
| Price Fair Value | (1.36) | (1.29) | |
| Enterprise Value | 3.8 M | 3.6 M |
The analysis of Evoke Pharma's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Evoke Pharma's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Evoke Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.303 |
Basic technical analysis of Evoke Stock
As of the 4th of May, Evoke Pharma shows the Mean Deviation of 3.81, variance of 28.65, and Standard Deviation of 5.35. Evoke Pharma technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate data for thirteen technical drivers for Evoke Pharma, which can be compared to its peers. Please confirm Evoke Pharma variance and potential upside to decide if Evoke Pharma is priced favorably, providing market reflects its regular price of 0.49 per share. As Evoke Pharma is a penny stock we also recommend to verify its jensen alpha numbers.Evoke Pharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Evoke Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Evoke Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Evoke Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hill Malcolm R over six months ago Acquisition by Hill Malcolm R of 14625 shares of Evoke Pharma subject to Rule 16b-3 |
Understand Evoke Pharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Evoke Pharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | 0.9662 | |||
| Mean Deviation | 3.81 | |||
| Coefficient Of Variation | (1,245) | |||
| Standard Deviation | 5.35 | |||
| Variance | 28.65 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.42) | |||
| Total Risk Alpha | (0.82) | |||
| Treynor Ratio | 0.9562 | |||
| Maximum Drawdown | 29.91 | |||
| Value At Risk | (7.46) | |||
| Potential Upside | 9.43 | |||
| Skewness | 0.8755 | |||
| Kurtosis | 2.69 |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | 0.9662 | |||
| Mean Deviation | 3.81 | |||
| Coefficient Of Variation | (1,245) | |||
| Standard Deviation | 5.35 | |||
| Variance | 28.65 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.42) | |||
| Total Risk Alpha | (0.82) | |||
| Treynor Ratio | 0.9562 | |||
| Maximum Drawdown | 29.91 | |||
| Value At Risk | (7.46) | |||
| Potential Upside | 9.43 | |||
| Skewness | 0.8755 | |||
| Kurtosis | 2.69 |
Consider Evoke Pharma's intraday indicators
Evoke Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Evoke Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 1945.26 | |||
| Daily Balance Of Power | 0.3333 | |||
| Rate Of Daily Change | 1.07 | |||
| Day Median Price | 0.45 | |||
| Day Typical Price | 0.47 | |||
| Price Action Indicator | 0.05 | |||
| Period Momentum Indicator | 0.03 |
Evoke Stock media impact
Far too much social signal, news, headlines, and media speculation about Evoke Pharma that are available to investors today. That information is available publicly through Evoke media outlets and privately through word of mouth or via Evoke internal channels. However, regardless of the origin, that massive amount of Evoke data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Evoke Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Evoke Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Evoke Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Evoke Pharma alpha.
Evoke Pharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Evoke Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Evoke Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Idea Analyzer Now
Idea AnalyzerAnalyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
| All Next | Launch Module |
How to buy Evoke Stock?
To provide specific investment advice or recommendations on Evoke Pharma stock, we recommend investors consider the following general factors when evaluating Evoke Pharma. This will help you to make an informed decision on whether to include Evoke Pharma in one of your diversified portfolios:- Examine Evoke Pharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Evoke Pharma's leadership team and their track record. Good management can help Evoke Pharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Evoke Pharma's business and its evolving consumer preferences.
- Compare Evoke Pharma's performance and market position to its competitors. Analyze how Evoke Pharma is positioned in terms of product offerings, innovation, and market share.
- Check if Evoke Pharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Evoke Pharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Evoke Pharma stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Evoke Pharma is a good investment.
Already Invested in Evoke Pharma?
The danger of trading Evoke Pharma is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Evoke Pharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Evoke Pharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Evoke Pharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Evoke Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Evoke Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Evoke Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Evoke Pharma Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evoke Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for Evoke Stock analysis
When running Evoke Pharma's price analysis, check to measure Evoke Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evoke Pharma is operating at the current time. Most of Evoke Pharma's value examination focuses on studying past and present price action to predict the probability of Evoke Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evoke Pharma's price. Additionally, you may evaluate how the addition of Evoke Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |
Is Evoke Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. If investors know Evoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evoke Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.33) | Revenue Per Share 1.55 | Quarterly Revenue Growth 1.105 | Return On Assets (0.49) | Return On Equity (10.35) |
The market value of Evoke Pharma is measured differently than its book value, which is the value of Evoke that is recorded on the company's balance sheet. Investors also form their own opinion of Evoke Pharma's value that differs from its market value or its book value, called intrinsic value, which is Evoke Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evoke Pharma's market value can be influenced by many factors that don't directly affect Evoke Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Evoke Pharma's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Evoke Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evoke Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.